CD274 and neoplasm: Among patients with tumor PD-L1 expression level of 1% or more (nivolumab, n = 11; placebo, n = 8), the median DFS was 29.67 months (95% CI 2.63–NR) in the nivolumab group and 25.95 months (95% CI 5.59–NR) in the placebo group (Fig. 2).